OAM
ACIU icon

Oxford Asset Management’s AC Immune ACIU Stock Holding History

Oxford Asset Management’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-29,431
Closed -$251K – 220
2019
Q4 		$251K Buy
+29,431
New +$196K 0.01% 1488
2019
Q1 		– Sell
-22,847
Closed -$216K – 1623
2018
Q4 		$216K Buy
+22,847
New +$216K 0.01% 1512

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Oxford Asset Management's ACIU Position: Q1 2020 in Review

Oxford Asset Management sold out of AC Immune (ACIU) in Q1 2020, closing a stake of 29,431 shares — an estimated $251K sold.

Oxford Asset Management first reported a position in ACIU in Q4 2018 and held it in 2 quarters. The position peaked at $251K in Q4 2019. 50 funds tracked by Wall St. Rank hold ACIU as of Q1 2020.

  • Oxford Asset Management reported no remaining AC Immune position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 29,431 AC Immune shares in Q1 2020, an estimated $251K.
  • Oxford Asset Management first reported a position in AC Immune in Q4 2018 and held it in 2 quarters.
  • Oxford Asset Management's AC Immune position peaked at $251K in Q4 2019.
  • 50 funds tracked by Wall St. Rank held AC Immune as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.